Company news

Immunic, Inc. news in 2019

Immunic, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips

November 18, 2019

Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson

October 14, 2019

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

October 9, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in October

September 29, 2019

Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

September 17, 2019

Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019

September 10, 2019

Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range

September 4, 2019

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis

August 11, 2019

Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity

August 7, 2019

Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project

July 31, 2019

Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer

July 15, 2019

Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update

June 20, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in June

May 29, 2019

Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

April 11, 2019

Decks in 2019